ARHGAP35
ARHGAP35 (Rho GTPase-activating protein 35) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Bladder & urothelial cancer, Breast cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Rho GTPase-activating protein (GAP). Binds several acidic phospholipids which inhibits the Rho GAP activity to promote the Rac GAP activity. This binding is inhibited by phosphorylation by PRKCA. Involved in cell differentiation as well as cell adhesion and migration, plays an important role in retinal tissue morphogenesis, neural tube fusion, midline fusion of the cerebral hemispheres and mammary gland branching morphogenesis. Transduces signals from p21-ras to the nucleus, acting via the ras GTPase-activating protein (GAP). Transduces SRC-dependent signals from cell-surface adhesion molecules, such as laminin, to promote neurite outgrowth. Location: Cytoplasm, cytoskeleton, cilium basal body; Cytoplasm; Nucleus; Cell membrane (UniProt). Locus 19q13.32 (HGNC).
- Endometrial cancer: Open Targets association 0.61 with endometrial cancer (MONDO_0011962); IntOGen driver in 4 cohorts (UCEC)
- Bladder & urothelial cancer: IntOGen driver in 3 cohorts (BLCA, UTUC)
- Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"ARHGAP35" OR ABSTRACT:"ARHGAP35" OR TITLE:"Rho GTPase activating protein 35" OR ABSTRACT:"Rho GTPase activating protein 35" OR TITLE:"Rho GTPase-activating protein 35" OR ABSTRACT:"Rho GTPase-activating protein 35" OR TITLE:"GRF-1" OR ABSTRACT:"GRF-1" OR TITLE:"p190ARhoGAP" OR ABSTRACT:"p190ARhoGAP" OR TITLE:"P190A" OR ABSTRACT:"P190A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARHGAP35, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/arhgap35.json. Licence CC BY-NC 4.0.